CALL US:022-2204 0015 / 16 / 17
Gireesh Babu, New Delhi December 03 , 2021
The Department of Pharmaceuticals (DoP) has advised the four states which received in-principle approval to set up medical devices parks to work together so as to complement each other in terms of capabilities. The Department has also weeded out around 4,900 files through a special drive in the month of October.

The DoP has conducted a meeting on October 20, under the chairmanship of secretary of the Department, with the four states to discuss the design of the upcoming medical devices parks. Under the scheme ‘Promotion of Medical Devices Parks’, four states - Himachal Pradesh, Tamil Nadu, Madhya Pradesh and Uttar Pradesh were given in-principle approval through letters on September 24, 2021.

“The states were advised to work together in collaboration so as to complement each other so that all target segments can be converted efficiently. Each state should take up the focus segment of the medical devices which will be manufactured in the park on the basis of its respective strength,” said the Department in its monthly summary report for the month of October.

These States were also advised to visit two to three medical device companies or medical devices clusters and to come up with three to four possible investors for the park. They were also asked to finalise the technical partner for the project at the earliest, it added.

A meeting convened with Dr R S Sharma, CEO, National Health Authority (NHA) to discuss the subject of tracking of availability of stocks of drugs, during the month, discussed the need for having an IT enabled system to track the availability of stocks of Covid management drugs in the supply chain down to retailer.

The DoP, in a special drive during October, reviewed almost 8,020 physical files, of which 4,900 files were weeded out, apart from conducting 12 cleanliness drives at three locations of the department.

During the month, the Drugs Coordination Committee meeting was also held, in which procurement orders placed by states and Union Territories for Covid-19 drugs’ buffer stock; adequacy of raw material supply with regard to manufacture of drugs used in Covid-19 treatment; update on monoclonal antibodies licensed for import/manufacture/marketing; exports of remdesivir and amphotericin B and manufacturing and availability of intravenous immunoglobulin (IVIG) were reviewed.

In October, the Department recommended exports of 34,02,415 vials of remdesivir and 6,11,567 units of amphotericin B to the Directorate General of Foreign Trade (DGFT), under the Ministry of Commerce and Industry. With the exports of remdesivir injection and active pharmaceutical ingredients and amphotericin-B injections were restricted in June, the DGFT has been referring applications for export in this regard to DoP and department of health and family welfare for recommendations.

The Department has also conducted the ninth session of India-Cyprus Joint Committee on Economic Scientific, Technical and Industrial Cooperation (JCEC) and first joint working group meeting under the MoU between India and Italy on cooperation in the field of health and medical sciences wherein areas of collaboration identified included investments in pharma and medical device sector in India.

The meeting also discussed the partnership between National Institutes of Pharmaceutical Education and Research (NIPERs) and foreign counterpart towards nurturing and promoting quality and excellence in pharmaceutical education and research, speedy WHO pre qualification programme for drugs and vaccines manufactured in India and industry to industry collaboration to promote resilient and diversified supply chains for the world.

The National Pharmaceutical Pricing Authority (NPPA) has established its 20th Price Monitoring and Resource Unit in Puducherry.

The DoP started the month of October with 16 pending applications for Foreign Direct Investments (FDIs), and received one more proposal during the month. It has disposed of two proposals in the month, leaving 15 proposals pending at the end of the month.

Share This Story

Leave a Reply
Your name (required)   Your email (required)
Website (required)
Enter Code (Required)





That foods might provide therapeutic benefits is clearly not a new concept. ...


About Us
Contact Us
News Archives

Product Finder
Features and Articles
Chronicle Pharmabiz
Food & Bevergae News
Ingredients South Asia
Media Information
Rate Card
Copyright © 2013 Saffron Media Pvt Ltd. All Rights Reserved.
Best View in Internet Explorer(9.0) or Firefox(26.0)